93M
This is the staggering number of adults in the United States who are at high-risk for serious vision loss.
Our impact
The scientific innovations made possible by generous donations have had a profound impact on people’s lives around the world.
2x
By 2050, the estimated number of people with age-related macular degeneration (AMD) is expected to more than double.
2.2B
The number of people who have a vision impairment. Almost half could have been prevented.
Our worldwide reach
See the impact we’ve had across the globe
San Francisco, California
SCORPIO (Seasonal Conjunctivitis Outbreak Reporting for Prevention and Improved Outcomes): An epidemiologic study to assess the major causes of bacterial conjunctivitis worldwide. In collaboration with Oregon Health and Science University, University of Nebraska, and University of California, Los Angeles.
See other locations
USA
ADJUST (Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): A randomized clinical trial assessing when to withdraw adalimumab in patients with juvenile idiopathic arthritis-associated uveitis. Also located in the United Kingdom and Australia.
Yurimaguas, Peru
mHealth: Developing a mobile application that will allow photo-diagnosis of trachoma, as well as visual acuity assessment and autorefraction for children who may need glasses.
United Kingdom
ADJUST (Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): A randomized clinical trial assessing when to withdraw adalimumab in patients with juvenile idiopathic arthritis-associated uveitis. Also located in the United States of America and Australia.
Three regions in Burkina
Faso, Africa
MIRAMA (Mortalité infantile réduite par l’administration de masse de l’azithromycine; Infant Mortality Reduced by the Mass Administration of Azithromycin): A collaboration with Helen Keller International (HKI) to assess repeated distribution of azithromycin to infants for childhood mortality.
Dosso, Niger
PNSO (Programme National de Promotion de la Santé Oculaire), CRISP (Children's Rehabilitation Institute and Surgical Program), & MOH (Ministry of Health): AVENIR is a cluster-randomized trial assessing the effectiveness of mass azithromycin for childhood mortality.
Kinshasa, Democratic Republic
of Congo, Africa
Auranofin for river blindness: A randomized trial of an old drug auranofin, repurposed to see if it has efficacy against onchocerciasis, the cause of river blindness. The objective is to see whether auranofin can kill adult worms, currently the biggest challenge preventing global elimination of river blindness.
Amhara, Ethiopia
KETFO (Kebele Elimination of Trachoma for Ocular Health): A cluster-randomized trial to determine the minimal core group for antibiotic treatment for the elimination of trachoma.
Bharatpur, Nepal
VIEW II (Village-Integrated Eye Worker Trial II): Village-based screening of people 60 years and older for glaucoma, diabetic retinopathy, and age-related macular degeneration; the objective is to determine whether village-based screening for these diseases (and linkage to care and treatment) ultimately leads to better vision at the community level.
Madurai, India
CUP (Corneal Ulcer Prevention): Training community health workers how to diagnose and treat corneal abrasions in rural India and Nepal, with the goal of preventing abrasions from developing into a full-fledged corneal infection. (Corneal infections are the second highest cause of blindness in India).
Bangkok, Thailand
STACCATO (Systemic and Topical Control of Cytomegalovirus Anterior uveitis: Treatment Outcomes): A randomized trial to assess the efficacy of different antiviral treatments for cytomegalovirus (CMV) anterior uveitis.
Chiang Mai, Thailand
Telemedicine for CMV retinitis: Studies in assessing the diagnostic accuracy of using simple retinal cameras at the primary care doctor’s office to diagnose CMV retinitis. The goal is to catch the disease earlier, before it causes blindness.
Hanoi, Vietnam
Corneal ulcer diagnostics: Assessment of “portable PCR” - in other words, bringing a sophisticated lab test to the doctor’s office and speeding the diagnosis, especially of fungal and amoebic corneal infections.
Australia
ADJUST (Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): A randomized clinical trial assessing when to withdraw adalimumab in patients with juvenile idiopathic arthritis-associated uveitis. Also located in the United Kingdom and the United States of America.
In the Community
Providing access to high-quality care is central to our mission. Thanks to generous support from funders, we’ve been able to ensure that people in our community who are under- or uninsured can get the medical attention they deserve by establishing partnerships at local hospitals and pop-up clinics for particularly vulnerable populations.
We aim to provide the most inclusive care possible, which ultimately serves everyone in our community. By working with diverse groups of people, we have the opportunity to learn how diseases impact groups of people in different ways and then tailor our interventions based on what we learn.
Community Support Initiative
The free UCSF Ophthalmology Shelter Clinic, operating within Division Circle Navigation Center (DCNC), is seeking funding support through All May See Foundation, to enhance our ongoing efforts in providing essential eye care services to the unhoused population at DCNC. Their mission is to eliminate barriers to eye care for the underserved and to prevent avoidable vision loss through early detection and treatment. To achieve this mission, they are seeking funding to acquire crucial ophthalmic equipment and sustain the clinic’s operations, ensuring that every individual theyserve has the opportunity for better vision and quality of life.